117 results match your criteria: "Centre de Référence des Maladies Rares "Maladies Neuromusculaires"[Affiliation]"

Introduction/aims: Neurolymphomatosis is a hematological condition defined by the direct infiltration of malignant lymphomatous cells into the peripheral nervous system. Since nerve conduction studies may disclose demyelinating features, clinicians may misdiagnose neurolymphomatosis as chronic inflammatory demyelinating polyneuropathy (CIDP). This study aimed to determine whether patients with neurolymphomatosis met the 2021 revised criteria for CIDP.

View Article and Find Full Text PDF
Article Synopsis
  • The study aimed to understand how patients with myasthenia gravis (MG) perceive their condition and identify potential improvements in treatment.
  • Patients over 12 months with the disease participated in an online survey, resulting in 246 completed responses.
  • Key findings highlighted participants' desires for better physical activity, reduced fatigue, and suggested treatment improvements, including fewer side effects and simpler medication regimens.
View Article and Find Full Text PDF
Article Synopsis
  • * Researchers analyzed data from 275 CMTX1 patients across 13 centers in France, finding that those with mutations in transmembrane domains had more severe symptoms and earlier onset than those with mutations in intracellular or extracellular domains.
  • * The findings suggest that the type of genetic mutation not only helps diagnose CMTX1 but also predicts disease severity, emphasizing the need to consider these correlations in upcoming clinical research.
View Article and Find Full Text PDF

[Laboratories directory: Mapping of the French neuromuscular research].

Med Sci (Paris)

November 2024

Société francophone du nerf périphérique (SFNP) - Service de neurologie, Hôpital Nord, CHU Saint-Étienne, France.

View Article and Find Full Text PDF

[The clinical actionability of genes: A concept for rare diseases and the first objective assessment for myopathies].

Med Sci (Paris)

November 2024

Aix-Marseille Université, Inserm, Marseille Medical Genetics, U1251 ; Département de Génétique Médicale, Hôpital Timone Enfants, APHM, Marseille, France.

Article Synopsis
  • High-throughput sequencing has revealed "actionable genes" that are associated with diseases having specific treatments or care.
  • Accurate genetic diagnosis is essential in starting interventions that can prevent or delay rare diseases, but increased analysis requests can delay results.
  • A French study identified 63 actionable genes in myopathies, highlighting the potential for improved patient prognosis, yet many rare diseases still lack specific treatments, emphasizing the need for ongoing research.
View Article and Find Full Text PDF

Gene therapy for hearing loss: Current status and future prospects of non-viral vector delivery systems.

Hear Res

November 2024

Univ Brest, INSERM, EFS, UMR 1078 GGB-GTCA team, 29200 Brest, France; CHU de Brest, Service de Génétique Médicale et Biologie de la Reproduction, Centre de Référence des Maladies Rares "Maladies Neuromusculaires", 29200 Brest, France. Electronic address:

Current therapeutic options for hearing loss rely on hearing aids, ossiculoplasty or cochlear implants. These devices have limitations, particularly in noisy acoustic environments. Therefore, interest in exploring aetiological treatments to improve not only auditory perception but also the quality of life of those affected is increasing.

View Article and Find Full Text PDF

Neuralgic amyotrophy presentation of acute intermittent porphyria: A case report.

J Peripher Nerv Syst

December 2024

Service d'ENMG et de pathologies neuromusculaires, centre de référence des maladies neuromusculaires PACA-Réunion-Rhône-Alpes, Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, Groupement Est, Bron, France.

Article Synopsis
  • Porphyrias are genetic disorders that affect heme production, with acute hepatic porphyrias (AHP) like acute intermittent porphyria (AIP) often mimicking neurological conditions, leading to potential misdiagnoses.
  • A 41-year-old woman experienced symptoms resembling neuralgic amyotrophy but was ultimately diagnosed with AIP after finding elevated levels of porphobilinogen and delta-aminolevulinic acid, following an initial misdiagnosis.
  • This case highlights the importance of considering AIP in patients with acute neuropathies, particularly when they present with abdominal symptoms, to ensure timely and effective treatment.
View Article and Find Full Text PDF

Extracellular vesicles (EVs) are future promising therapeutics, but their instability in vivo after administration remains an important barrier to their further development. Many groups evaluated EV surface modification strategies to add a targeting group with the aim of controlling EV biodistribution. Conversely, fewer groups focused on their stabilization to obtain "stealth" allogenic EVs.

View Article and Find Full Text PDF

[Proposals from a French expert panel for respiratory care in ALS patients].

Rev Mal Respir

October 2024

Neurophysiologie respiratoire expérimentale et clinique, Inserm UMRS1158, Sorbonne université, Paris, France; Département R3S, service de pneumologie, groupe hospitalier Pitié-Salpêtrière, AP-HP, Paris, France.

Background: Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by progressive diaphragm weakness and deteriorating lung function. Bulbar involvement and cough weakness contribute to respiratory morbidity and mortality. ALS-related respiratory failure significantly affects quality of life and is the leading cause of death.

View Article and Find Full Text PDF

Caffeine consumption outcomes on amyotrophic lateral sclerosis disease progression and cognition.

Neurobiol Dis

September 2024

University of Lille, Inserm, CHU Lille, UMR-S1172 Lille Neuroscience & Cognition (LilNCog), Lille, France; Department of Medical Pharmacology, CHU de Lille, Lille, France. Electronic address:

Caffeine consumption outcomes on Amyotrophic Lateral Sclerosis (ALS) including progression, survival and cognition remain poorly defined and may depend on its metabolization influenced by genetic variants. 378 ALS patients with a precise evaluation of their regular caffeine consumption were monitored as part of a prospective multicenter study. Demographic, clinical characteristics, functional disability as measured with revised ALS Functional Rating Scale (ALSFRS-R), cognitive deficits measured using Edinburgh Cognitive and Behavioural ALS Screen (ECAS), survival and riluzole treatment were recorded.

View Article and Find Full Text PDF

Early Maintenance Treatment Initiation and Relapse Risk Mitigation After a First Event of MOGAD in Adults: The MOGADOR2 Study.

Neurology

August 2024

From the Department of Neurology (R.D.); Clinical Research Department (J.G.), Rothschild Foundation Hospital, Paris; Department of Neurology (J.C.), University Hospital of Toulouse; Department of Neurology (B.A.), Pôle de Neurosciences Cliniques, APHM, Aix Marseille University, Hôpital de la Timone; Department of Neurology (A.R.), University Hospital of Bordeaux; Centre de référence des maladies inflammatoires rares du cerveau et de la moelle (MIRCEM) (E.M., C.G.), Department of Neurology, AP-HP, Pitié-Salpêtrière Hospital, Paris; Centre de référence des maladies inflammatoires rares du cerveau et de la moelle (MIRCEM) (J.P., L.B., R.M.), Department of Neurology, sclérose en plaques, pathologies de la myéline et neuro-inflammation, Hôpital Neurologique Pierre Wertheimer; Department of Neurology (D.A.L.), CR2TI-Inserm U1064, CIC1314, Nantes Université, University Hospital of Nantes; Department of Neurology (L. Michel), INSERM UMR 1236, Université de Rennes 1, University Hospital of Rennes, Rennes, France; Center for Clinical Investigation (N.C.), INSERM U1434; Biopathology of Myelin, Neuroprotection and Therapeutic Strategy, INSERM U1119; Department of Neurology, University Hospital of Strasbourg; CRC SEP Neurologie Pasteur 2 (M.C.), University Hospital of Nice, Université Cote d'Azur, UMR2CA (URRIS), Nice; CRC SEP (X.A.), CRMR Leukofrance, Department of Neurology, INM / U1298, Gui de Chauliac Hospital, University Hospital of Montpellier; Department of Neurology (E.T.), University Hospital of Nimes; CRC SEP (H.Z.), Department of Neurology, U 1172, University Hospital of Lille; Department of Neurology (B.B.), University Hospital of Rouen; Neuro Ophthalmology Unit (C.F.T.), Hospices Civils de Lyon, Claude Bernard Lyon 1 University, Lyon Neuroscience Research Center CRNL U1028 UMR 5292, IMPACT F-69500, Neurological Hospital of Lyon; Department of Neurology (T.M.), University Hospital of Dijon; Department of Neurology (P.C.), University Hospital of la Rochelle; Department of Neurology (P.K.), Hospital of Luxembourg, Luxembourg-Ville, Luxembourg; Department of Child Neurology and Child Intensive Care Unit (S.C.), Hospital of Pau; Department of Neurology (N. Maubeuge), University Hospital of Poitiers; Department of Neurology (K.H.), Delafontaine Hospital, Saint-Denis; Department of Neurology (C.N.), Andre Mignot hospital, Hospital of Versailles, Le Chesnay; Department of Neurology (E.B.), University Hospital of Besancon; Department of Neurology (H.M.), Sud Francilien Hospital, Corbeil-Essonnes; CRC SEP Limoges/Poitiers (L. Magy), CRMR Maladies Neuromusculaires AOC (FILNEMUS), UR 2018 NeurIT, University Hospital of Limoges; Department of Neurology (F.K.), Meaux Hospital; Department of Neurology (M.S.R.), University Hospital of Bicêtre, Le Kremlin-Bicêtre; Department of Neurology (L.H.), Felix Guyon University Hospital, Saint Denis, Reunion; Department of Neurology (M.G.), Hospital of Valenciennes; Department of Neurology (P.B.), University Hospital of Caen Normandie; CRC SEP (A.M.), Department of Neurology, University Hospital of Tours, Bretonneau Hospital; Department of Neurology (G.M.), Nancy University Hospital; Université de Lorraine, EA 4360 APEMAC, Vandoeuvre-Lès-Nancy; Department of Neurology (M.M.), University Hospital of Reims; Department of Neurology (N. Mélé), Sainte-Anne Hospital, GHU Paris Psychiatrie et Neurosciences, Paris Cité University, INSERM 1266; and Department of Neurology (C.P.), Rothschild Foundation Hospital, Paris, France.

Article Synopsis
  • MOGAD (myelin oligodendrocyte glycoprotein antibody-associated disease) is a new autoimmune disorder, and this study aims to examine the long-term outcomes and factors affecting relapse in adult patients.
  • The research included 128 patients from a French cohort with a follow-up period averaging over 6.5 years; results showed that a significant portion experienced relapses, with specific onset symptoms such as optic neuritis and myelitis.
  • Findings indicated that starting maintenance treatment after the first attack is linked to lower relapse risk, with notable impact on patients' disability scores over time.
View Article and Find Full Text PDF

[Pediatric myasthenia with ocular involvement].

J Fr Ophtalmol

September 2024

Service d'ophtalmologie, Paris-Cité University, hôpital universitaire Necker-Enfants-Malades, AP-HP, Paris, France; Centre de recherche des Cordeliers, Sorbonne Paris-Cité University, Paris, France.

Purpose: Myasthenia is a rare disease in children, with an estimated incidence of 1 to 5 per million children. However, the potential severity of its consequences and the existence of specific treatments require prompt diagnosis by pediatric ophthalmologists.

Methods: Retrospective review of patient records.

View Article and Find Full Text PDF

Primary mitochondrial disorders and mimics: Insights from a large French cohort.

Ann Clin Transl Neurol

June 2024

Service de génétique, Institut de Biologie en santé, CHU Angers, Univ Angers, INSERM, CNRS, MITOVASC, Equipe MitoLab, SFR ICAT, Angers, France.

Objective: The objective of this study was to evaluate the implementation of NGS within the French mitochondrial network, MitoDiag, from targeted gene panels to whole exome sequencing (WES) or whole genome sequencing (WGS) focusing on mitochondrial nuclear-encoded genes.

Methods: Over 2000 patients suspected of Primary Mitochondrial Diseases (PMD) were sequenced by either targeted gene panels, WES or WGS within MitoDiag. We described the clinical, biochemical, and molecular data of 397 genetically confirmed patients, comprising 294 children and 103 adults, carrying pathogenic or likely pathogenic variants in nuclear-encoded genes.

View Article and Find Full Text PDF

Objective: We aimed to describe characteristics of patients with ATTR variant polyneuropathy (ATTRv-PN) and ATTRv-mixed and assess the real-world use and safety profile of tafamidis meglumine 20mg.

Methods: Thirty-eight French hospitals were invited. Patient files were reviewed to identify clinical manifestations, diagnostic methods, and treatment compliance.

View Article and Find Full Text PDF

Neutral Block Copolymer Assisted Gene Delivery using Hydrodynamic Limb Vein Injection.

Macromol Biosci

July 2024

Institut Parisien de Chimie Moléculaire, Equipe Chimie des Polymères, Sorbonne University, UMR 8232 CNRS, Paris, 75005, France.

Article Synopsis
  • Three different families of amphiphilic block copolymers are synthesized to explore improvements in gene delivery methods using Hydrodynamic Limb Vein (HLV) injections.
  • The first family includes polyoxazoline-based copolymers with various substituents, followed by a triblock copolymer featuring a thermosensitive middle block.
  • Results indicate that simple amphiphilic block copolymers are ineffective for enhancing gene transfection, but incorporating double or triple amphiphilic copolymers with a low critical solution temperature improves performance significantly, while the molar mass has little impact.
View Article and Find Full Text PDF

Introduction: Neuromuscular diseases (NMDs) include a large group of heterogeneous diseases. NMDs frequently involve gait disorders, which affect quality of life. Several walking tests and tools have been described in the literature, but there is no consensus regarding the use of walking tests and tools in NMDs or of their measurement properties for walking outcomes.

View Article and Find Full Text PDF
Article Synopsis
  • In 2017, nusinersen, an injectable treatment for spinal muscular atrophy (SMA), was introduced, followed by the oral treatment risdiplam in 2020, leading to questions about appropriate care for adults with SMA due to limited data.
  • To standardize treatment access in France, a national SMA multidisciplinary team meeting (SMDT) was established in 2018 to support decision-making for adult patients.
  • An analysis of 107 patient cases showed that the SMDTs provided various treatment recommendations based on consultations, with most requests aimed at starting new treatments (nusinersen or risdiplam).
View Article and Find Full Text PDF

Mucoactive drugs and multiple applications in pulmonary disease therapy.

Eur J Pharm Biopharm

January 2024

Univ Brest, INSERM, EFS, UMR 1078, GGB, F-29200 Brest, France; CHU de Brest, Service de Génétique Médicale et de Biologie de la Reproduction, 29200 Brest, France; CHU de Brest, Centre de Référence des Maladies Rares Maladies Neuromusculaires, 29200, Brest France. Electronic address:

Mucus is a complex polymeric hydrogel that serves as a critical defense in several organs. In the lungs, it provides a formidable barrier against inhaled particles such as microorganisms. In addition, mucus is essential for normal lung physiology, as it promotes immune tolerance and facilitates a normal commensal pulmonary microbiome.

View Article and Find Full Text PDF

Background: Respiratory complications resulting from motor neurons degeneration are the primary cause of death in amyotrophic lateral sclerosis (ALS). Predicting the need for non-invasive ventilation (NIV) in ALS is important for advance care planning and clinical trial design. The aim of this study was to assess the potential of quantitative MRI at the brainstem and spinal cord levels to predict the need for NIV during the first six months after diagnosis.

View Article and Find Full Text PDF
Article Synopsis
  • Hereditary transthyretin amyloidosis (ATTRv) is a genetic disease that typically starts in adults and leads to progressive nervous system issues, but there are effective treatments available.
  • A study conducted in France over five years analyzed 553 patients over 50 with progressive nerve problems, finding that 2.7% had pathogenic gene variants linked to ATTRv, primarily the Val30Met variant.
  • Patients with ATTRv were more likely to experience symptoms like severe weight loss and orthostatic hypotension, and the diagnosis allowed for specific treatments and identified additional cases in family members, emphasizing the importance of early detection.
View Article and Find Full Text PDF

BSV163/DOPE-mediated TRAIL gene transfection acts synergistically with chemotherapy against cisplatin-resistant ovarian cancer.

Chem Biol Drug Des

January 2024

Univ Brest, Inserm, EFS, UMR 1078, GGB, GTCA Team, "Gene Transfer and Combined therapeutic Approaches", Brest, France.

Ovarian cancer is the seventh most frequently diagnosed cancer among women worldwide. Most patients experience recurrence and succumb eventually to resistant disease, underscoring the need for an alternative treatment option. In the presented manuscript, we investigated the effect of the TRAIL-gene, transfected by an innovative bioinspired lipid vector BSV163/DOPE in the presence or absence of cisplatin, to fight against sensitive and resistant ovarian cancer.

View Article and Find Full Text PDF

In inflammatory myopathies, dropped head/bent spine syndrome is associated with scleromyositis: an international case-control study.

RMD Open

September 2023

Exploration fonctionnelle musculaire, Service de Physiologie Explorations Fonctionnelles Musculaires, Hôpitaux Universitaires de Strasbourg, Université de Strasbourg, Strasbourg, France

Article Synopsis
  • Some myopathies can cause dropped head or bent spine syndrome (DH/BS), but its significance in inflammatory myopathies (IM) hasn't been thoroughly explored.
  • A study compared 49 patients with DH/BS related to IM to 98 control IM patients, finding that those with DH/BS were older and had more severe symptoms, including upper limb weakness, dysphagia, and muscle atrophy.
  • The results suggest that DH/BS serves as a marker for the severity of IM and is often linked to complications related to systemic sclerosis, highlighting its clinical importance.
View Article and Find Full Text PDF

Background And Aims: Emery-Dreifuss muscular dystrophy (EDMD) is caused by variants in EMD (EDMD1) and LMNA (EDMD2). Cardiac conduction defects and atrial arrhythmia are common to both, but LMNA variants also cause end-stage heart failure (ESHF) and malignant ventricular arrhythmia (MVA). This study aimed to better characterize the cardiac complications of EMD variants.

View Article and Find Full Text PDF

Characteristics of Patients With Late-Onset Pompe Disease in France: Insights From the French Pompe Registry in 2022.

Neurology

August 2023

From the Neurology Department (C.L., N.T., P.L.), Raymond Poincaré University Hospital, Garches, APHP; Nord-Est-Ile-de-France Neuromuscular Reference Center (C.L., C.T., A.B., A.N.-P., M.M., H.P., N.T., A.A., P.L.), FHU PHENIX; Biostatistics Unit (DRCI) (M.D.A.), Clermont-Ferrand University Hospital; Service d'Electroneuromyographie et Pathologies Neuromusculaires (F.B.), Hospices Civils de Lyon; Inserm (C.T.), Lille University Hospital Center, U1172, Lille Neuroscience & Cognition, University of Lille; Centre de Référence des Maladies Neuromusculaires (E.S.-C., S.A.), Hôpital Timone Adultes, Assistance Publique Hôpitaux de Marseille; PACA Réunion Rhône Alpes Reference Center for Neuromuscular Diseases (E.S.-C., S.A.), FILNEMUS; Department of Neurology (E.L.), Grenoble University Hospital; APHP (A.B., A.A.), Service de Neuromyologie, Institut de Myologie, GH Pitié Salpêtrière, Paris; Neuromuscular Reference Center (G.S.), Bordeaux University Hospital (Pellegrin), University of Bordeaux; Neurology Department (J.-B.N.), Neuromuscular Center, CHRU Cavale Blanche, Brest; Peripheral Nervous System and Muscle Department (S.S.), Université Cote d'Azur, CHU de Nice; Centre de Référence des Maladies Neuromusculaires AOC (A.M.), CHU Hôtel Dieu, Nantes; Department of Neurology (A.N.-P.), University Hospital, Strasbourg; Centre de Référence des Maladies Neuromusculaires Rares Rhône-Alpes (A.L.), Hôpital Nord, CHU de Saint-Etienne; ALS Center (S.B.), Francois-Rabelais University, Tours, Centre-Val de Loire; Neuromuscular Reference Center (M.S.), Department of Neurology, University Hospital, Angers; Département de Neurologie (P.C.), Hôpital Purpan, CHU Toulouse; Department of Neurology (D.R.), CHU Nîmes, University of Montpellier, Nîmes; Department of Neurology (M.M.), Nancy University Hospital; Neuromuscular Reference Center (A.-L.B.-M.), Rouen University Hospital; Service de Physiologie et Explorations Fonctionnelles (H.P.), GH Paris Ile de France Ouest, Site Raymond Poincaré, APHP, Garches; U1179 INSERM (H.P., P.L.), Université Versailles Saint Quentin en Yvelines, Paris-Saclay; and Centre Hospitalo-Universitaire de Montpellier (D.H.), Hôpital Arnaud-de-Villeneuve, France.

Article Synopsis
  • The French Pompe Disease Registry was established in 2004 to track the progress of the disease in patients and evaluate the long-term effects of enzyme replacement therapy (ERT) with alglucosidase-alfa.
  • An update on 210 patients from the registry reveals that the median age of participants was almost 49, with many initially presenting symptoms like muscle weakness and respiratory issues, affecting their mobility significantly.
  • The findings indicate that awareness among doctors has improved, leading to earlier diagnoses and a decrease in the severity of cases at the time of inclusion, highlighting the registry's role in understanding and managing Pompe disease effectively.
View Article and Find Full Text PDF